China approves Livzon Pharmaceutical's COVID vaccine as a booster
With COVID cases on the rise in China, the government has approved Livzon Pharmaceutical's COVID-19 vaccine as a booster, in hopes of having as many people boosted as possible.
Pfizer and BioNTech COVID vaccine 73.2% effective in children under 5, according to new data
Pfizer Inc and BioNTech's COVID vaccine was approved for use in children under 5 years old in June, and new studies have shown the vaccine to be 73.2% effective within that age group.
Pfizer looks for US approval on updated COVID booster that targets omicron variant
Pfizer Inc and BioNTech announced on Monday that they are looking for the U.S. to approve their retooled COVID booster, which targets the omicron variant.
Curevac sues BioNTech over COVID-19 vaccine's mRNA technology
CureVac is suing Pfizer's German partner BioNTech for alleged patent infringement related to the development of their mRNA vaccines against COVID-19.
FDA authorizes Pfizer booster shots for kids ages 5-11
The U.S. Food and Drug Administration (FDA) amended the emergency use authorization for Pfizer-BioNTech COVID-19 vaccine. The agency is allowing the use of a single booster dose in kids ages 5 to 11.
Pfizer COVID-19 vaccine less effective in ages 5-11: study
Two doses of the Pfizer Inc. and BioNTech SE COVID-19 vaccine was protective against severe disease in children aged 5 to 11 during the recent omicron variant surge, but quickly lost most of its ability to prevent infection in the age group, according to a study by New York State researchers.
Pfizer submits request for COVID-19 vaccine use in children under age 5
Pfizer and BioNTech said Tuesday that the companies had asked the Food and Drug Administration (FDA) to authorize their COVID-19 vaccine for emergency use in children younger than 5 years old.
Pfizer, BioNTech begin omicron-specific COVID-19 vaccine study
COVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.
Pfizer expects updated COVID-19 vaccine data for kids under 5 by April
Pfizer Inc. expects the latest results from a clinical trial for kids under the age of 5 of the COVID-19 vaccine it developed with Germany's BioNTech SE by April, a top company scientist said on Wednesday.
Pfizer CEO on omicron variant: Booster will be enough to maintain protection
Pfizer CEO Albert Bourla said Wednesday that the company's COVID-19 booster shot would be enough to "maintain protection" against the omicron variant.